EMEA-000715-PIP05-13-M04

Key facts

Invented name
Otezla
Active substance
apremilast
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0389/2019
PIP number
EMEA-000715-PIP05-13-M04
Pharmaceutical form(s)
  • Tablet
  • Oral suspension
Condition(s) / indication(s)
Treatment of Behcet disease
Route(s) of administration
Oral use
Contact for public enquiries
Amgen Europe B.V. 

E-mail: medinfointernational@amgen.com
Tel. +44 (0)1223 420305

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating
Average
2 ratings